Study Finds Portola’s Oral Anticoagulant Not Superior To Injectable Treatment
The California-based pharmaceutical company's stock fell 28 percent at the news.
Portola's Long-Acting Blood Thinner Misses Main Study Goal
Portola Pharmaceuticals Inc said late-stage data showed its oral anticoagulant was not superior to an injectable standard therapy in preventing blood clots in acutely ill patients. ... An estimated 20 million acutely ill patients in the G7 countries are at risk of developing [blood clots] either while in the hospital or following discharge, San Francisco, California-based Portola estimates. (Grover, 3/24)